Fig. 3

1-way sensitivity analysis. a In any value of pLowRisk (proportion of low-risk patients), surveillance was associated with higher exposure of chemotherapy; b When pRelapseHighrisk (relapse rate of high-risk group) > 0.365, surveillance was associated with higher exposure of chemotherapy; c When pRelapsePostPrimChemo (relapse rate after primary chemotherapy) < 0.287, surveillance was associated with higher exposure of chemotherapy; d in any value of pRelapseLowrisk (relapse rate of low-risk group), surveillance was associated with higher exposure of chemotherapy; e in any value of pRelapsePostSalvChemo (relapse rate after salvage chemotherapy), surveillance was associated with higher exposure of chemotherapy; f in any value of tSecondChemo (toxicity utility of second-line chemotherapy compared to salvage chemotherapy), surveillance was associated with higher exposure of chemotherapy. Red: risk-adapted treatment, blue: surveillance